Stoke Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
STOK$27.21-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of operations and comprehensive loss
| Year EndedDecember 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue | $184,420 | $36,555 |
| Operating expenses: | ||
| Research and development | 137,922 | 89,133 |
| Sales, general and administrative | 67,088 | 48,794 |
| Total operating expenses | 205,010 | 137,927 |
| Loss from operations | (20,590) | (101,372) |
| Other income (expense): | ||
| Interest income (expense), net | 13,756 | 12,638 |
| Other income (expense), net | (51) | (247) |
| Total other income (expense) | 13,705 | 12,391 |
| Net loss | $(6,885) | $(88,981) |
| Net loss per share—basic and diluted | $(0.12) | $(1.65) |
| Weighted average common shares outstanding—basic and diluted | 59,219,184 | 54,008,883 |
| Comprehensive loss: | ||
| Net loss | $(6,885) | $(88,981) |
| Other comprehensive loss: | ||
| Unrealized gain (loss) on marketable securities | 694 | (127) |
| Total other comprehensive gain (loss) | $694 | $(127) |
| Comprehensive loss | $(6,191) | $(89,108) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.